Important: Retatrutide is a research peptide only. It has not been approved by SAHPRA (South African Health Products Regulatory Authority) for clinical use. Learn more
Buy Retatrutide Pens in South Africa
Veyvora supplies retatrutide peptide pens with full batch documentation and Certificate of Analysis. Retatrutide is a triple-acting GLP-1/GIP/glucagon receptor agonist currently in Phase 3 clinical trials.
Key Takeaways
- Phase 2 trials showed up to 24.2% body weight reduction over 48 weeks (NEJM, 2023)
- Each pen ships with batch-specific Certificate of Analysis and third-party verification
- Triple hormone receptor mechanism targets GLP-1, GIP, and glucagon pathways simultaneously
- International shipping to South Africa with temperature-controlled packaging
Last updated: February 2026 | Based on published Phase 2 trial data | ClinicalTrials.gov
3rd-Party Tested
CoA Verified
Reported Results from South African Buyers
Self-reported weight changes from Veyvora customers in South Africa. These are individual experiences, not clinical data.
Disclaimer: The results below are self-reported by customers and have not been independently verified or conducted under clinical conditions. Individual outcomes depend on many factors. Retatrutide is not approved by SAHPRA. In clinical trials (NEJM, 2023), participants receiving the highest dose experienced a mean weight reduction of 24.2% over 48 weeks under controlled conditions.
12 weeks
Duration
-14.2 kg
Reported
103 kg
Start
16 weeks
Duration
-18.7 kg
Reported
112 kg
Start
10 weeks
Duration
-11.3 kg
Reported
95 kg
Start
20 weeks
Duration
-22.1 kg
Reported
118 kg
Start
Customer reports are collected via post-purchase surveys. Veyvora does not guarantee any specific results. Retatrutide is an investigational peptide not approved for clinical use by SAHPRA.
Veyvora Retatrutide Pen
Research-grade retatrutide peptide pen with batch documentation and Certificate of Analysis.
Retatrutide (LY3437943) is a triple-acting GLP-1/GIP/glucagon receptor agonist developed by Eli Lilly. Each Veyvora pen contains research-grade retatrutide peptide.
In Phase 2 clinical trials, participants receiving the highest dose experienced a mean 24.2% body weight reduction over 48 weeks.
Not approved by SAHPRA or any regulatory authority for clinical use.
Why Buy Retatrutide from Veyvora
Research-grade retatrutide peptide pens with documentation, verification, and international shipping to South Africa.
Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trial data published in NEJM showed up to 24.2% mean body weight reduction at the highest dose over 48 weeks.
Every pen ships with a batch-specific Certificate of Analysis (CoA) from independent third-party laboratories, verifying peptide identity, purity, and sterility.
International express delivery to Johannesburg, Cape Town, Durban, Pretoria, and all major South African cities. Orders are dispatched within 24 hours of payment confirmation.
Receive complete batch documentation including manufacturing records, storage guidelines, and handling instructions. All products include tamper-evident packaging.
Temperature-controlled shipping with insulated packaging and gel packs to maintain peptide integrity during international transit to South Africa.
Retatrutide is currently in Phase 3 trials. Phase 2 results also showed improvements in metabolic markers including HbA1c and liver fat reduction in participants with obesity.
Ships internationally to South Africa. Not approved by SAHPRA for clinical use.
Clinical Trial Evidence
Key findings from the Phase 2 retatrutide obesity trial, published in the New England Journal of Medicine.
Jastreboff AM, Kaplan LM, Frias JP, et al. N Engl J Med. 2023;389(6):514-526.
-24.2%
Mean body weight reduction (highest dose, 48 weeks)
338
Participants enrolled
48 weeks
Treatment duration
Observed Risks in Clinical Trials
The most commonly reported adverse events in Phase 2 trials were gastrointestinal in nature. These included:
- Nausea (reported in up to 45% of participants at higher doses)
- Diarrhoea, vomiting, and constipation
- Decreased appetite
- Dose-dependent increases in heart rate were also observed
Retatrutide is not approved by SAHPRA for clinical use. Phase 3 trials are ongoing. This information is provided for educational purposes only.
How to Use the Retatrutide Pen
Step-by-step instructions for handling your retatrutide pen. This guide is based on standard peptide pen administration procedures.
Dosing Context from Clinical Trials
In the Phase 2 NEJM trial, retatrutide was administered once weekly via subcutaneous injection. Doses were escalated from 0.5 mg starting dose up to a maximum of 12 mg over the 48-week study period. Dose escalation followed a protocol-defined schedule with increases at 4-week intervals. These are research protocols -- not prescribing instructions.
Prepare the Pen
Remove the retatrutide pen from refrigerated storage (2-8 degrees Celsius). Allow it to reach room temperature for approximately 30 minutes before use. Inspect the solution through the viewing window -- it should be clear and colourless. Do not use if discoloured or containing particles.
Attach the Needle
Remove a new pen needle from its sterile packaging. Align the needle with the pen tip and push straight on, then twist clockwise until secure. Remove the outer needle cap (keep it for disposal) and then the inner needle cap (discard). A small drop of liquid at the tip is normal.
Select the Dose
Turn the dose selector to set your prescribed dose. You will hear a click for each unit. The dose window will display the selected amount. If you set the wrong dose, simply turn the selector forwards or backwards to correct it without wasting any peptide.
Inject and Dispose
Pinch a fold of skin at the chosen injection site (abdomen, thigh, or upper arm). Insert the needle at a 90-degree angle. Press the dose button fully and hold for 10 seconds to ensure complete delivery. Release the skin, withdraw the needle, and apply gentle pressure if needed.
Pre-Injection Checklist
Regulatory Notice: Retatrutide is an investigational peptide. It has not been approved by SAHPRA (South African Health Products Regulatory Authority) for any medical indication. The usage information above is based on standard subcutaneous pen injection procedures and published clinical trial protocols. It does not constitute medical advice.
South African Customer Reviews
Feedback from verified Veyvora customers in South Africa. Reviews focus on product quality, packaging, and delivery experience.
Packaging was excellent -- arrived in insulated box with cold packs intact. Certificate of Analysis included as promised. Delivery took 6 business days to Sandton.
Very professional setup. Pen came with full batch documentation and clear instructions. Customs clearance was smooth, no issues getting it into SA.
CoA matched the batch number on the pen. Took about 8 days to arrive in Durban. Packaging was temperature-controlled and product was well-sealed.
Second order from Veyvora. Consistent quality between batches. The pen design is easy to use and the dosing markings are clear. Fast support response when I had questions.
Good communication throughout. Tracking was provided immediately. Product arrived well-packaged with all documentation. Would order again.
Impressed with the thoroughness -- batch records, CoA, storage instructions all included. This is the standard you expect from a research peptide supplier.
Reviews are from verified Veyvora purchases. They describe the buying and delivery experience, not medical outcomes. ID references available on request.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly. Unlike single-receptor GLP-1 drugs such as semaglutide (Ozempic/Wegovy), or dual-receptor agonists like tirzepatide (Mounjaro), retatrutide activates three receptors simultaneously: GLP-1, GIP, and glucagon.
In Phase 2 clinical trials published in the New England Journal of Medicine (2023), participants receiving the highest dose of retatrutide experienced a mean body weight reduction of 24.2% over 48 weeks -- the largest reduction reported for any obesity drug in a peer-reviewed trial at the time of publication. Phase 3 trials are currently underway, with results expected in 2025-2026.
How the Triple Receptor Mechanism Works
Reduces appetite and slows gastric emptying. The same target as semaglutide and liraglutide. Well-established in obesity and diabetes treatment.
Enhances insulin sensitivity and may improve fat metabolism. Also targeted by tirzepatide. Emerging evidence suggests synergy with GLP-1 activation.
Increases energy expenditure and promotes fat oxidation. This is the unique third target that distinguishes retatrutide from existing treatments.
Dosing Used in Clinical Trials
The following dose levels were used in the Phase 2 trial (NEJM, 2023). This is trial protocol information, not prescribing guidance.
| Dose Group | Weekly Dose | Escalation | Mean Weight Change at 48 Weeks |
|---|---|---|---|
| Low | 1 mg | No escalation | -8.7% |
| Medium | 4 mg | Start 2 mg, escalate at week 4 | -17.5% |
| Medium-High | 8 mg | Start 2 mg, escalate every 4 weeks | -22.8% |
| High | 12 mg | Start 2 mg, escalate every 4 weeks | -24.2% |
| Placebo | -- | -- | -2.1% |
Source: Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526. All doses administered once weekly via subcutaneous injection.
How Retatrutide Compares
Comparison based on published Phase 2/3 trial data. Direct comparison is limited as these were separate studies with different populations.
| Feature | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptors Targeted | GLP-1, GIP, Glucagon | GLP-1, GIP | GLP-1 only |
| Max Weight Loss (Trial) | -24.2% | -22.5% | -16.9% |
| Administration | Once weekly SC | Once weekly SC | Once weekly SC |
| Regulatory Status (SA) | Not approved by SAHPRA | SAHPRA review pending | SAHPRA approved (Wegovy) |
| Trial Phase | Phase 3 (ongoing) | Approved (some markets) | Approved (some markets) |
Data from separate trials with different protocols. Cross-trial comparisons have inherent limitations.
Documented Benefits & Known Limitations
- Up to 24.2% mean body weight reduction at highest dose
- Significant HbA1c reductions in participants with type 2 diabetes
- Reductions in liver fat (relevant to MASLD/NAFLD)
- Dose-dependent efficacy across multiple dose levels
- Once-weekly administration for convenience
- Not approved by SAHPRA or any regulatory authority
- GI side effects (nausea up to 45% at higher doses)
- Dose-dependent increases in heart rate observed
- Long-term safety data not yet available
- Phase 3 trials still ongoing -- final efficacy may differ
Frequently Asked Questions
Order Retatrutide Pens for Delivery to South Africa
Research-grade retatrutide peptide pens with Certificate of Analysis, batch documentation, and temperature-controlled international shipping.
Not approved by SAHPRA. Research purposes only. | info@veyvora.co
Related Reading
Detailed breakdown of dosing protocols used in clinical trials.
Side-by-side comparison of triple vs single receptor agonists.
How the triple agonist compares to the dual agonist.
What "research purposes only" means and SAHPRA regulatory context.